Balanços • Rigel Pharmaceuticals

RIGL

A Rigel Pharmaceuticals Inc desenvolve pequenas moléculas para doenças autoimunes, cancerosas e virais. O principal medicamento da empresa é um candidato à artrite reumatoide oral licenciado pela AstraZeneca. A Astra assumiu a responsabilidade geral de desenvolver e comercializar o medicamento e pagará royalties e marcos à Rigel. Seu produto principal inclui comprimidos de TAVALISSE, o único inibidor oral da tirosina quinase (SYK) do baço, fostamatinibe, R289, R552, R835, DS-3032, inibidores THF-beta e inibidor JAK inalado por AZD0449.

Tabela de balanços completa e atualizada com os principais indicadores financeiros: Lucro Líquido, Receita, EBTIDA, Margem, ROE, Dividendos

12/2014

10 balanços

12/2024

Ano	Receita Líq	EBITDA	Lucro Líq	Mrg Líq	Patrimônio	ROE	Dívida Líq	DL/EBITDA	FCO Aj	Capex	FCF	FCL Aj	LPA Dil
12/2015	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345
12/2016	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345
12/2017	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345
12/2018	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345
12/2019	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345
12/2020	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345
12/2021	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345
12/2022	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345
12/2023	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345
12/2024	179	29	17	10%	3	0%	-17	-	19	-0	-12	19	0.99

Para ver a tabela completa, você precisa ser Premium.